https://www.bioworld.com/rss en-us Indole-based compounds have been explored as antimalarial agents because they can disrupt the Plasmodium cell cycle. In a recent study, researchers from the University of São Paulo and the Federal University of São Carlos reported the evaluation of scaffolds selected from three classes of indole hybrids against Plasmodium falciparum. Plasmodium cell cycle. In a recent study, researchers from the University of São Paulo and the Federal University of São Carlos reported the evaluation of scaffolds selected from three classes of indole hybrids against Plasmodium falciparum.]]> http://www.bioworld.com/articles/732707 Fri, 17 Jul 2026 09:00:00 -0400 https://www.bioworld.com/articles/732707-new-indole-based-hybrids-emerge-as-resistance-resilient-antimalarial-leads Illustration of blood cells, Plasmodium causing malaria illness Respiratory syncytial virus (RSV) infection is responsible for 3.2 million hospital admissions and about 118,000 deaths in children under 5 years of age. The increased risk of RSV infection (and other infectious diseases) in young children is broadly attributed to their immature immune system. But researchers from University College London have published work suggesting that this is not the only reason. http://www.bioworld.com/articles/732703 Fri, 17 Jul 2026 09:00:00 -0400 https://www.bioworld.com/articles/732703-new-biomarker-may-improve-rsv-drug-screening 3D illustration of neutrophils New research has teased out specific aspects of how Epstein-Barr virus (EBV) sparks the immune response that leads on to the development of multiple sclerosis (MS), opening the way to the rational design of vaccines and antivirals that address the root cause of the disease. http://www.bioworld.com/articles/732721 Thu, 16 Jul 2026 09:00:00 -0400 https://www.bioworld.com/articles/732721-new-research-identifies-ebv-antigen-targets-for-ms-therapies Illustration of virus attacking neuron New research has teased out specific aspects of how Epstein-Barr virus (EBV) sparks the immune response that leads on to the development of multiple sclerosis (MS), opening the way to the rational design of vaccines and antivirals that address the root cause of the disease. http://www.bioworld.com/articles/732702 Wed, 15 Jul 2026 14:00:00 -0400 https://www.bioworld.com/articles/732702-new-research-identifies-ebv-antigen-targets-for-ms-therapies Illustration of virus attacking neuron U.S. Health and Human Services Secretary Robert Kennedy was the 800-pound gorilla that couldn’t be ignored as the Senate Health, Education, Labor and Pensions Committee held a joint confirmation hearing July 15 for President Donald Trump’s nominees for CDC director and the head of the Administration for Strategic Preparedness and Response. http://www.bioworld.com/articles/732609 Wed, 15 Jul 2026 12:00:00 -0400 https://www.bioworld.com/articles/732609-cdc-nominees-qualifications-shadowed-by-kennedy-agenda Erica Schwartz, CDC director nominee Erica Schwartz, nominee for CDC director, speaks at the Senate Health, Education, Labor and Pensions Committee joint confirmation hearing held July 15. Credit: help.senate.gov Island Pharmaceuticals Ltd. has secured government and ethics approvals to deploy its investigational antiviral galidesivir in patients infected during the escalating Bundibugyo Ebola outbreak in Africa, giving the small Australian biotech a rare opportunity to collect prospective human data in an active filovirus emergency. http://www.bioworld.com/articles/732671 Tue, 14 Jul 2026 12:00:00 -0400 https://www.bioworld.com/articles/732671-island-pharma-targets-ebola-species-lacking-approved-treatments Ebola virus The Oxford Vaccine Group has delivered on its promise, and after starting work in mid-May has completed preclinical testing and is ready to begin a phase I trial of a vaccine against the Bundibugyo Ebola virus that is causing the current serious disease outbreak in the Democratic Republic of Congo. http://www.bioworld.com/articles/732596 Tue, 14 Jul 2026 12:00:00 -0400 https://www.bioworld.com/articles/732596-first-purpose-designed-ebola-bundibugyo-vaccine-ready-for-phase-i Close-up of a medical syringe Researchers from the Centre National de la Recherche Scientifique, the Institut National de la Santé et de la Recherche Médicale, Nanyang Technological University and the University of Montpellier have patented new Mycobacterium sp. ATP synthase (F0F1 ATPase) inhibitors potentially useful for the treatment of nontuberculous mycobacterial infections. Mycobacterium sp. ATP synthase (F0F1 ATPase) inhibitors potentially useful for the treatment of nontuberculous mycobacterial infections.]]> http://www.bioworld.com/articles/732638 Tue, 14 Jul 2026 09:00:00 -0400 https://www.bioworld.com/articles/732638-cnrs-and-collaborators-discover-new-emmycobacterium-em-atpase-inhibitors Human cytomegalovirus (CMV) is a clinical challenge in infants and immunocompromised individuals, since no licensed vaccine exists. Vaccine development is complex due to several factors, including viral latency, genomic complexity and immune evasion, among others. Evaxion A/S recently presented data on its proprietary AI-immunology platform used to create the EVX-V1 vaccine for CMV infection. http://www.bioworld.com/articles/732627 Tue, 14 Jul 2026 09:00:00 -0400 https://www.bioworld.com/articles/732627-preclinical-data-support-evaxions-platform-behind-cmv-vaccine-candidate Cytomegalovirus in a human cell The Global Health Innovative Technology (GHIT) Fund is investing approximately ¥2.86 billion ($18 million) in six R&D projects for the development of drugs for malaria, tuberculosis (TB) and neglected tropical diseases. http://www.bioworld.com/articles/732564 Mon, 13 Jul 2026 09:00:00 -0400 https://www.bioworld.com/articles/732564-ghit-fund-buoys-malaria-tb-neglected-tropical-disease-research Various pills laid across a target Cancer researchers are increasingly turning to the microbiome to understand why some patients respond well to treatment while others face severe complications. Gut microbial communities shift during intensive therapies such as bone marrow transplantation, and those changes influence infection risk, immune recovery and long‑term survival. New advances in microbial sequencing and engineering redefine this community as a measurable clinical parameter that can be monitored, modeled, and even therapeutically reshaped to improve outcomes in oncology and other conditions. http://www.bioworld.com/articles/732621 Fri, 10 Jul 2026 09:00:00 -0400 https://www.bioworld.com/articles/732621-microbial-ecology-reshapes-cancer-care-diagnostics-and-therapies Illustration of bacteria, microorganisms in the gastrointestinal system Researchers from Chongqing Medical University have presented data regarding an antiviral compound, KM-10411, derived from a FUBP1 inhibitor (FUBP1-IN-1), as a potential approach to treat hepatitis B virus (HBV) infections. http://www.bioworld.com/articles/732551 Fri, 10 Jul 2026 09:00:00 -0400 https://www.bioworld.com/articles/732551-km-10411-shows-anti-hbv-effects-dependent-on-dusp5 Hepatitis B virus What appears to be a routine item on a routine list of the U.S. Department of Health and Human Services’ (HHS) proposed rulemakings for the next fiscal year is being seen as anything but routine, given HHS Secretary Robert Kennedy’s stance on vaccines and several commonly used drugs. http://www.bioworld.com/articles/732516 Thu, 09 Jul 2026 12:00:00 -0400 https://www.bioworld.com/articles/732516-covid-19-injuries-posting-of-crls-on-hhs-2027-rulemaking-agenda US flag and HHS logo Credit: mehaniq41 Island Pharmaceuticals Ltd. has secured government and ethics approvals to deploy its investigational antiviral galidesivir in patients infected during the escalating Bundibugyo Ebola outbreak in Africa, giving the small Australian biotech a rare opportunity to collect prospective human data in an active filovirus emergency. http://www.bioworld.com/articles/732432 Wed, 08 Jul 2026 12:00:00 -0400 https://www.bioworld.com/articles/732432-island-pharma-targets-ebola-species-lacking-approved-treatments Ebola virus Chronic liver disease and hepatocellular carcinoma (HCC) associated with chronic hepatitis B virus (HBV) are serious health problems in highly endemic areas. Investigators from the National Health Research Institutes have developed a protein-based recombinant vaccine, rHBx-rHBc149, for this unmet medical need. http://www.bioworld.com/articles/732485 Wed, 08 Jul 2026 09:00:00 -0400 https://www.bioworld.com/articles/732485-recombinant-vaccine-inhibits-hbv-associated-hcc-growth Liver with hepatitis viruses, blood cells Cancer researchers are increasingly turning to the microbiome to understand why some patients respond well to treatment while others face severe complications. Gut microbial communities shift during intensive therapies such as bone marrow transplantation, and those changes influence infection risk, immune recovery and long‑term survival. New advances in microbial sequencing and engineering redefine this community as a measurable clinical parameter that can be monitored, modeled, and even therapeutically reshaped to improve outcomes in oncology and other conditions. http://www.bioworld.com/articles/732480 Wed, 08 Jul 2026 09:00:00 -0400 https://www.bioworld.com/articles/732480-microbial-ecology-reshapes-cancer-care-diagnostics-and-therapies Illustration of bacteria, microorganisms in the gastrointestinal system Researchers from IRBM SpA described the discovery and preclinical profile of IRBM-Z-2, a Zika virus NS2B-NS3 protease inhibitor. http://www.bioworld.com/articles/732361 Thu, 02 Jul 2026 09:00:00 -0400 https://www.bioworld.com/articles/732361-oral-antiviral-irbm-z-2-targets-zika-infection Zika virus particles. Zika virus particles (red) shown in African green monkey kidney cells. Credit: National Institute of Allergy and Infectious Diseases, NIH Ipsen SA announced its second acquisition of the week, saying it will pay €700 million (US$797 million) for Memo Therapeutics AG and its phase III-ready drug potravitug, a treatment for BK virus-associated infections and nephropathy in immune-compromised kidney transplant patients. http://www.bioworld.com/articles/732257 Wed, 01 Jul 2026 12:00:00 -0400 https://www.bioworld.com/articles/732257-in-2nd-deal-of-week-ipsen-buys-memos-kidney-transplant-antibody Illustration of antibodies flying around a kidney Telum Therapeutics SL has completed an €18 million (US$24 million) series A financing to advance its lead program targeting hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia caused by the multidrug-resistant gram-negative pathogen Acinetobacter baumannii. Acinetobacter baumannii.]]> http://www.bioworld.com/articles/732332 Wed, 01 Jul 2026 09:00:00 -0400 https://www.bioworld.com/articles/732332-telum-therapeutics-advances-antimicrobials-with-series-a-funding Euro symbol in piggy bank Smartbax GmbH has announced the successful second closing of its pre-series A financing round for a total of €6.3 million (US$7.2 million) as it advances development of next-generation antibiotics against multidrug-resistant bacteria. http://www.bioworld.com/articles/732311 Tue, 30 Jun 2026 09:00:00 -0400 https://www.bioworld.com/articles/732311-smartbax-raises-additional-funds-to-advance-antibiotic-pipeline Illustration of medical professionals, research It is known that bacterial cells exchange biological matter, but it is not clear whether bacteria can exchange functional proteins. In a recent paper published in Science on June 25, 2026, researchers from Baylor College of Medicine and their collaborators investigated horizontal protein transfer between bacteria, specifically between protein-donor Escherichia coli and protein-receiving E. coli that could turn into persister cells and tolerate lethal antibiotic doses or a stressful environment. Science on June 25, 2026, researchers from Baylor College of Medicine and their collaborators investigated horizontal protein transfer between bacteria, specifically between protein-donor Escherichia coli and protein-receiving E. coli that could turn into persister cells and tolerate lethal antibiotic doses or a stressful environment.]]> http://www.bioworld.com/articles/732308 Tue, 30 Jun 2026 09:00:00 -0400 https://www.bioworld.com/articles/732308-antibiotics-spur-protein-transfer-that-boosts-bacterial-survival Petri dish and capsules Boyuan Pharmaceutical (Suzhou) Co. Ltd. has divulged new pyridone derivatives potentially useful for the treatment of HIV infection. http://www.bioworld.com/articles/732218 Mon, 29 Jun 2026 09:00:00 -0400 https://www.bioworld.com/articles/732218-anti-hiv-compounds-reported-in-boyuan-pharmaceutical-patent Jiangxi Kerui Pharmaceutical Co. Ltd. has disclosed new prodrugs of fungal GPI-anchored wall transfer protein 1 (GWT1) inhibitors potentially useful for the treatment of fungal infections. http://www.bioworld.com/articles/732217 Mon, 29 Jun 2026 09:00:00 -0400 https://www.bioworld.com/articles/732217-jiangxi-kerui-pharmaceutical-patents-new-fungal-gwt1-inhibitors For the second time this year, the U.S. CDC’s Advisory Committee on Immunization Practices (ACIP) canceled a scheduled meeting due to a federal judge’s stay that keeps the panel from meeting with its current membership. Typically, ACIP meets three times a year – in February, June and October. The 2026 June meeting was slated for June 23-25. Whether the adcom meets in October will be up to the courts and how far Health and Human Services Secretary Robert Kennedy digs in his heels to maintain a hand-picked committee tilted toward his view of vaccines. http://www.bioworld.com/articles/732159 Thu, 25 Jun 2026 12:00:00 -0400 https://www.bioworld.com/articles/732159-uncertainty-reigns-as-acip-remains-on-court-hold Empty meeting room CNCCS SCARL Collezione Nazionale Dei Composti Chimici E Centro Screening and IRBM SpA have patented new serine protease NS3/nonstructural protein 2B (NS3/NS2B) (flavivirus) inhibitors potentially useful for the treatment of West Nile and Zika virus infections. http://www.bioworld.com/articles/732143 Thu, 25 Jun 2026 09:00:00 -0400 https://www.bioworld.com/articles/732143-italian-researchers-discover-new-flavivirus-ns3-ns2b-inhibitors RQ Biotechnology Ltd. has completed an oversubscribed $115 million (£85.5 million) series A financing to advance its long-acting antibody therapeutics for the prevention of influenza in high-risk and immunocompromised populations. http://www.bioworld.com/articles/732130 Thu, 25 Jun 2026 09:00:00 -0400 https://www.bioworld.com/articles/732130-series-a-financing-at-rq-bio-to-advance-rqb-01-for-flu-prevention Woman with blanket on couch blowing her nose with a tissue Some proteins embedded in the structure of prions may have antimicrobial activity, according to a study led by scientists at the University of Pennsylvania. An AI analysis of millions of fragments from prion-related proteins has revealed more than a thousand peptides that disrupt bacterial membranes and reduce infection in animal models, suggesting these proteins could be an unexpected source of new antibiotics. http://www.bioworld.com/articles/732127 Thu, 25 Jun 2026 09:00:00 -0400 https://www.bioworld.com/articles/732127-ai-uncovers-hidden-antibiotic-potential-in-prion-proteins AI-generated visualization of prion protein clusters When it comes to vaccines and preparedness, platform delivery technologies can be both a boon and a barrier. On the one hand, an existing platform can speed development of a vaccine targeting an unexpected viral scare such as the recent Bundibugyo Ebola and Andes hantavirus outbreaks. On the other hand, the intellectual property (IP) protecting that platform adds to the economic hurdles facing smaller vaccine developers, Douglas Bucklin, a life sciences patent attorney with Volpe Koenig, told BioWorld. BioWorld.]]> http://www.bioworld.com/articles/732079 Wed, 24 Jun 2026 12:00:00 -0400 https://www.bioworld.com/articles/732079-platform-technology-ip-adds-to-vaccine-challenge Virtual IP display The outbreak of hantavirus infection first reported on the MV Hondius cruise ship on May 2 is all but over, with most isolating passengers, crew members and other contacts leaving quarantine over the past week, as the 42-day incubation period drew to an end. http://www.bioworld.com/articles/732078 Wed, 24 Jun 2026 12:00:00 -0400 https://www.bioworld.com/articles/732078-who-to-declare-hantavirus-outbreak-over-as-quarantines-end Hantavirus cells Molecular subtyping of disease is typically associated with cancer. Now, researchers at the University of Cambridge are applying it to infections. http://www.bioworld.com/articles/732184 Wed, 24 Jun 2026 09:00:00 -0400 https://www.bioworld.com/articles/732184-pulmonary-inflammation-unveils-three-severe-pneumonia-subtypes Lungs anatomy